Mortality Rate From Infectious Diseases Holding Steady in U.S.

Share this content:
Mortality Rate From Infectious Diseases Holding Steady in U.S.
Mortality Rate From Infectious Diseases Holding Steady in U.S.

WEDNESDAY, Nov. 23, 2016 (HealthDay News) -- The U.S. mortality rate from infectious diseases is about the same now as it was in 1980, but some of the specific disease threats have changed over the years, according to a research letter published in the Nov. 22/29 issue of the Journal of the American Medical Association.

Heidi Brown, Ph.D., M.P.H., an assistant professor in epidemiology and biostatistics at the University of Arizona in Tucson, and colleagues found that the national mortality rate from infections stood at 45.6 deaths per 100,000 people in 2014. That compared with 42.0 per 100,000 in 1980. The overall mortality rate rose as high as 63.5 per 100,000 in 1995, owing to the HIV/AIDS epidemic. AIDS deaths declined from then on, with the introduction of medication regimens that have turned HIV into a manageable chronic disease.

Overall, deaths from any infectious cause fell substantially between 1900 and 1950, with the exception of a spike during the 1918 flu pandemic. Focusing on more recent years, the investigators found that mortality was somewhat higher in 2014, versus 1980. Pneumonia and influenza were the most common causes, accounting for 38.3 percent of infectious disease deaths during that time period. The mortality rate from pneumonia and the flu held steady between 1980 and 2014, at 17.1 per 100,000.

Brown's team also found that mortality from vector-borne infections rose slightly. That was related to the introduction of the West Nile virus in 1999. Since 2002, the average yearly mortality rate from all vector-borne infections has stood at 0.05 deaths per 100,000 people.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease


Sign up for myCME e-newsletters


More in Home

FDA OKs Lynparza to Treat Breast Cancer With BRCA Mutation

FDA OKs Lynparza to Treat Breast Cancer With ...

PARP inhibitor therapy already approved to treat BRCA-mutated ovarian cancer

Ceramide-Infused Skin Barrier Cuts Stoma-Related Costs

Ceramide-Infused Skin Barrier Cuts Stoma-Related Costs

Use of ceramide-infused barrier tied to lower stoma-related care costs, improved patient satisfaction

Non-Ventilator Hospital-Acquired Pneumonia Risk Affects All Ages

Non-Ventilator Hospital-Acquired Pneumonia Risk Affects All Ages

Non-vent-associated HAP risk occurs in all hospital units; risk extends even to low-risk/younger patients

is free, fast, and customized just for you!

Already a member?

Sign In Now »